CAM HSBIOTECH Stock (03069.HK) Real-time Quotes - Financial Data - Analyst Ratings

Company Encyclopedia

CAM HSBIOTECH

03069.HK

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

Innovent, first Chinese biotech firm to market weight-loss drug, joins Hang Seng Index

Innovent Biologics will join the Hang Seng Index next month, increasing the number of constituents to 89. The biotech firm recently signed an $11.4 billion deal with Takeda Pharmaceuticals. Innovent, China Hongqiao Group, and Yum China Holdings will also join the Hang Seng China Enterprises Index. The Hang Seng Index has risen nearly 30% this year. Innovent's stock has climbed 138.4% this year. ASMPT will be removed from the Hang Seng Tech Index, while ENN Energy Holdings, Haidilao International, and New Oriental Education & Technology Group will be deleted from the Hang Seng China Enterprises Index.

南华早报·5 Hours ago

Top 10 HK Stock Losers (11.21)

GANFENGLITHIUM(01772) fell 12.47%, with a trading turnover 2.1 Billion HKD, and a year-to-date rose 155.3%. CHONGQING M&E(02722) fell 12.32%, with a trading turnover 83.1 Million HKD, and a year-to-date rose 149.7%. CHINA NEXT-GEN(03928) fell 12.18%, with a trading turnover 6.0 Million HKD, and a year-to-date rose 295.2%.

LB Select·10 Hours ago

LB Select·10 Hours ago

BUZZ-3SBio drops most in seven months on unit spin-off plans

3SBio Inc's shares dropped 8.9% to HK$29.52, marking the largest decline since April, due to plans to spin off its 87.16%-owned unit, Mandi Inc, for a separate listing on the Hong Kong stock exchange. The Stock Exchange confirmed the spin-off, with 3SBio not retaining any interest in Mandi post-listing. Despite the drop, 3SBio's stock is up 400% YTD, while the Hang Seng Biotech Index rose 77%.

Reuters·12 Hours ago

3SBio spin-off Mandi banks on hair-loss and weight-loss drugs in Hong Kong IPO bid

Mandi, a consumer healthcare arm of 3SBio backed by Alibaba Health, filed for an IPO in Hong Kong, focusing on its minoxidil hair-loss products. The IPO aims to leverage Hong Kong's booming market, with plans to use the capital for product expansion and R&D. 3SBio will exit its stake in Mandi, which will raise funds through a global offering. Mandi's net profit rose 14.5% to 390.3 million yuan in 2024, and it is developing new drugs in phase III trials.

南华早报·13 Hours ago